Molecular basis of agonism and antagonism in the oestrogen receptor
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Oestrogens are involved in the growth, development and homeostasis of a number of tissues. The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER). Hormone binding to the ligand-binding domain (LBD) of the ER initiates a series of molecular events culminating in the activation or repression of target genes. Transcriptional regulation arises from the direct interaction of the ER with components of the cellular transcription machinery. Here we report the crystal structures of the LBD of ER in complex with the endogenous oestrogen, 17beta-oestradiol, and the selective antagonist raloxifene, at resolutions of 3.1 and 2.6 A, respectively. The structures provide a molecular basis for the distinctive pharmacophore of the ER and its catholic binding properties. Agonist and antagonist bind at the same site within the core of the LBD but demonstrate different binding modes. In addition, each class of ligand induces a distinct conformation in the transactivation domain of the LBD, providing structural evidence of the mechanism of antagonism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We previously found that the full-length ERα dimer forms a symmetric tail-to-tail dimer in the ERα/SRC-3/p300 complex (Yi et al., 2015), consistent with the nature of palindromic DNA binding sequence, symmetric X-ray crystal structures of the ERα LBD (Brzozowski et al., 1997) and DBD dimers (Schwabe et al., 1993).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Brzozowski et al., 1997
In the citing paper
“the AR LBD interacts weakly with LXXLL motif-containing coactivators, such as SRCs, (Brzozowski et al., 1997; Dubbink et al., 2006; He et al., 2004; He et al., 1999; Matias et al., 2000; Nadal et al., 2017).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Brzozowski et al., 1997
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475 · cited 1×
“Data were integrated and reduced using the programs DENZO and SCALEPAC”
MethodPROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions
Wallace, A. C., Laskowski, R. A., & Thornton, J. M. (1995) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/8.2.127 · Cited by 5,690
MOLECULAR MECHANISMS OF ACTION OF STEROID/THYROID RECEPTOR SUPERFAMILY MEMBERS
Tsai, M.-J., & O'Malley, B. W. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.002315 · Cited by 2,932 · cited 1×
“The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER”
BackgroundThe estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer
Kumar, V., & Chambon, P. (1988) · Cell · doi:10.1016/0092-8674(88)90017-7 · Cited by 1,220 · cited 1×
“The ER LBDs are arranged as non-crystallographic dimers within both the E 2 and RAL complex crystals in a manner consistent with both the oligomeric state of liganded ER in solutio”
BackgroundCrystal structure of the ligand-binding domain of the human nuclear receptor RXR-α
Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H., & Moras, D. (1995) · Nature · doi:10.1038/375377a0 · Cited by 1,177 · cited 1×
“The overall architecture of the ER LBD (helices H3–H12) is similar to that seen in the crystal structures of other nuclear receptor LBD”
BackgroundCrystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid
Renaud, J.-P., Rochel, N., Ruff, M., Vivat, V., Chambon, P., Gronemeyer, H., & Moras, D. (1995) · Nature · doi:10.1038/378681a0 · Cited by 1,097 · cited 1×
“The overall architecture of the ER LBD (helices H3–H12) is similar to that seen in the crystal structures of other nuclear receptor LBD”
BackgroundA canonical structure for the ligand-binding domain of nuclear receptors
Wurtz, J.-M., Bourguet, W., Renaud, J.-P., Vivat, V., Chambon, P., Moras, D., & Gronemeyer, H. (1996) · Nature Structural Biology · doi:10.1038/nsb0196-87 · Cited by 985 · cited 1×
“, and emphasizes the universal nature of this fold within this receptor superfamil”
Background
Cited by
Items 301–400 of 1,012
Lambert, M. N. T., Thybo, C. B., Lykkeboe, S., Rasmussen, L. M., Frette, X., Christensen, L. P., & Jeppesen, P. B. (2017) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.117.153353 · Cited by 210
“, bone tissue, bone marrow, adipose, brain, kidney, endothelial cells, and liver) (18, 19).”
Identification of COUP-TFII Orphan Nuclear Receptor as a Retinoic Acid–Activated Receptor
Kruse, S. W., Suino-Powell, K., Zhou, X. E., Kretschman, J. E., Reynolds, R., Vonrhein, C., Xu, Y., Wang, L., Tsai, S. Y., Tsai, M.-J., et al. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060227 · Cited by 209
“The antagonist-bound ERa structures also share similarity to the structure of COUP-TFII with the relative positioning of the AF2 helix [21,24].”
Escande, A., Pillon, A., Servant, N., Cravedi, J.-P., Larrea, F., Muhn, P., Nicolas, J.-C., Cavaillès, V., & Balaguer, P. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.02.002 · Cited by 208
Yao, K. A., Lee, E. S., Bentrem, D. J., England, G. M., Schafer, J. M., O'Regan, R. M., & Jordan, V. C. (2000) · PubMed · Cited by 208
Characterization of the estrogenic activities of zearalenone and zeranol in vivo and in vitro
Takemura, H., Shim, J.-Y., Sayama, K., Tsubura, A., Zhu, B. T., & Shimoi, K. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2006.08.008 · Cited by 207
Kemppainen, J. A. (1999) · Molecular Endocrinology · doi:10.1210/me.13.3.440 · Cited by 207
Understanding nuclear receptor form and function using structural biology
Rastinejad, F., Huang, P., Chandra, V., & Khorasanizadeh, S. (2013) · Journal of Molecular Endocrinology · doi:10.1530/jme-13-0173 · Cited by 207
“Elegant principles for rationally converting a receptor agonist to an antagonist were introduced through the crystallographic characterizations of ERs (Brzozowski et al .”
BackgroundInfluentialByrne, C., Divekar, S. D., Storchan, G. B., Parodi, D. A., & Martin, M. B. (2013) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-013-9273-9 · Cited by 206
“Following the binding of estradiol, the receptor is phosphorylated on serines in the A/B region that increases the activity of the AF-1 domain [16, 17] and a conformational change occurs in the LBD leading to the dissociation of the heat shock complex and the formation of the AF-2 domain, the coactivator binding site…”
BackgroundChemoprevention of breast cancer with selective oestrogen-receptor modulators
Jordan, V. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2048 · Cited by 206
“It is reasonable to ask how does the ligand programme the receptor complex to interact with other proteins? X-ray crystallography of the ligand-binding domains of the ER bound to either oestrogens or anti-oestrogens shows the potential of ligands to promote co-activator binding or prevent co-activator binding on the b…”
BackgroundThe Hair Follicle as an Estrogen Target and Source
Ohnemus, U., Uenalan, M., Inzunza, J., Gustafsson, J.-A., & Paus, R. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0020 · Cited by 205
Self-citationRogatsky, I., Trowbridge, J. M., & Garabedian, M. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.32.22296 · Cited by 205
Binding of Ligands and Activation of Transcription by Nuclear Receptors
Steinmetz, A. C. U., Renaud, J.-P., & Moras, D. (2001) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.30.1.329 · Cited by 205
Mohler, M. L., Bohl, C. E., Jones, A., Coss, C. C., Narayanan, R., He, Y., Hwang, D. J., Dalton, J. T., & Miller, D. D. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900280m · Cited by 205
Endocrine Disruptors: Present Issues, Future Directions
Crews, D., Willingham, E., & Skipper, J. K. (2000) · The Quarterly Review of Biology · doi:10.1086/393498 · Cited by 204
Ruff, M., Gangloff, M., Wurtz, J., & Moras, D. (2000) · Breast Cancer Research · doi:10.1186/bcr80 · Cited by 204
McDonnell, D. P., & Wardell, S. E. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.09.007 · Cited by 203
Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy
Shao, W., & Brown, M. (2003) · Breast Cancer Research · doi:10.1186/bcr742 · Cited by 203
“ing and prevents the formation of the coactivator-binding surface [71–73].”
BackgroundPark, O. J., & Surh, Y.-J. (2004) · Toxicology Letters · doi:10.1016/j.toxlet.2003.06.001 · Cited by 203
An, J., Ribeiro, R. C. J., Webb, P., Gustafsson, J.-Å., Kushner, P. J., Baxter, J. D., & Leitman, D. C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15161 · Cited by 203
Self-citationHodges, Y. K., Tung, L., Yan, X.-D., Graham, J. D., Horwitz, K. B., & Horwitz, L. D. (2000) · Circulation · doi:10.1161/01.cir.101.15.1792 · Cited by 202
DNA binding alters coactivator interaction surfaces of the intact VDR–RXR complex
Zhang, J., Chalmers, M. J., Stayrook, K. R., Burris, L. L., Wang, Y., Busby, S. A., Pascal, B. D., Garcia-Ordonez, R. D., Bruning, J. B., Istrate, M. A., et al. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2046 · Cited by 201
“This observation is similar to those obtained by HDX studies on estrogen receptor α ( ERα ), in which estradiol (E2) binding did not impact HDX within H12, yet the co-crystal structure of E2– ERα showed a similar ligand-dependent repositioning of H12 in the absence of direct contact between H12 and ligan”
ResultTamoxifen treatment and gynecologic side effects: a review
MOURITS, M. (2001) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(00)01196-0 · Cited by 200
“This molecular explanation of the agonistic and antagonistic effects of the ligand-binded estrogen receptor is further supported by others.(22,23) Hormone binding to the ligand binding domain of the estrogen receptor initiates a series of molecular events culminating in the activation or repression of target genes.”
BackgroundKuruto-Niwa, R., Nozawa, R., Miyakoshi, T., Shiozawa, T., & Terao, Y. (2005) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2004.05.009 · Cited by 200
Selective Interaction of Vitamin D Receptor with Transcriptional Coactivators by a Vitamin D Analog
Takeyama, K.-I., Masuhiro, Y., Fuse, H., Endoh, H., Murayama, A., Kitanaka, S., Suzawa, M., Yanagisawa, J., & Kato, S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1049 · Cited by 200
“From the structural similarity of the ligand-binding domains of nuclear receptors, ligand type-specific alterations in their structures, at least in the helix 12 positions, are postulated (7).”
BackgroundGaido, K. W., Maness, S. C., McDonnell, D. P., Dehal, S. S., Kupfer, D., & Safe, S. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23119-9 · Cited by 199
“ERa and ERb antagonists such as raloxifene and hydroxytamoxifen contain bulky constituents that reposition helix 12 and block receptor interaction with coactivators (Brzozowski et al., 1997; Pike et al., 1999).”
de Mes, T. Z. D., Zeeman, G., & Lettinga, G. (2005) · Reviews in Environmental Science and Bio/Technology · doi:10.1007/s11157-005-3216-x · Cited by 199
“receptor because the binding pocket is nearly twice as large as the molecular volume of E2 (Brzozowski et al. 1997).”
BackgroundKawazu, M., Saso, K., Tong, K. I., McQuire, T., Goto, K., Son, D.-O., Wakeham, A., Miyagishi, M., Mak, T. W., & Okada, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017830 · Cited by 198
“conformational changes which facilitate cofactor recruitment [3], and forms multi-subunit protein complexes [4,5,6].”
BackgroundEstrogen-Like Activity of Ginsenoside Rg1 Derived from Panax notoginseng
Chan, R. Y. K. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.8.3691 · Cited by 197
Functions of estrogen and estrogen receptor signaling on skeletal muscle
Ikeda, K., Horie-Inoue, K., & Inoue, S. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105375 · Cited by 196
Chemical Genomics Profiling of Environmental Chemical Modulation of Human Nuclear Receptors
Huang, R., Xia, M., Cho, M.-H., Sakamuru, S., Shinn, P., Houck, K. A., Dix, D. J., Judson, R. S., Witt, K. L., Kavlock, R. J., et al. (2011) · Environmental Health Perspectives · doi:10.1289/ehp.1002952 · Cited by 196
“One potential cause for this low concordance is that antagonists need not bind as perfectly as do agonists to the LBD to antagonize the receptor activity (Brzozowski et al. 1997; Shiau et al. 1998).”
BackgroundGenomic actions of estrogen receptor α: what are the targets and how are they regulated?
Welboren, W.-J., Sweep, F. C. G. J., Span, P. N., & Stunnenberg, H. G. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-09-0086 · Cited by 152
“inhibits interaction with coactivators (Brzozowski et al. 1997).”
Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors.
Suetsugi, M., Su, L., Karlsberg, K., Yuan, Y.-C., & Chen, S. (2003) · PubMed · Cited by 196
Neurosteroids and GABA-A Receptor Function
Wang, M. (2011) · Frontiers in Endocrinology · doi:10.3389/fendo.2011.00044 · Cited by 195
“These groups are important for the binding of neurosteroids to a variety of proteins by means of hydrogenbinding with polar or charged residues (Brzozowski et al., 1997; Grishkovskaya et al., 2000).”
BackgroundThe nuclear receptor co-repressor Nrip1 (RIP140) is essential for female fertility
White, R., Leonardsson, G., Rosewell, I., Ann Jacobs, M., Milligan, S., & Parker, M. (2000) · Nature Medicine · doi:10.1038/82183 · Cited by 195
“This new surface results from a conformational change in the receptor in the presence of hormone that does not occur in the presence of antagonist”
BackgroundEstrogenic and antiproliferative properties of glabridin from licorice in human breast cancer cells.
Tamir, S., Eizenberg, M., Sömjen, D., Stern, N., Shelach, R., Kaye, A. D., & Vaya, J. (2000) · PubMed · Cited by 195
Incorporation of Prior Phase Information Strengthens Maximum-Likelihood Structure Refinement
Pannu, N. S., Murshudov, G. N., Dodson, E. J., & Read, R. J. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998004119 · Cited by 194
“Oestrogen receptor ± re®nement of partial structure and effect of `bad' and `good' phases This structure has been solved by a combination of MIR, multi-crystal NCS averaging and phased re®nement (Brzozowski et al., 1997).”
MethodStructure of the homodimeric androgen receptor ligand-binding domain
Nadal, M., Prekovic, S., Gallastegui, N., Helsen, C., Abella, M., Zielinska, K., Gay, M., Vilaseca, M., Taulès, M., Houtsmuller, A. B., et al. (2017) · Nature Communications · doi:10.1038/ncomms14388 · Cited by 193
Similarities and distinctions in the mode of action of different classes of antioestrogens.
Wakeling, A. E. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070017 · Cited by 193
Byrne, C., Divekar, S. D., Storchan, G. B., Parodi, D. A., & Martin, M. B. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.03.025 · Cited by 193
“Similar to other nuclear receptors (Wurtz et al., 1996;Renaud et al., 1996;Bourguet et al., 1995;Brzozowski et al., 1997;Wagner et al., 1995;Tanenbaum et al., 1998;Shiau et al., 1998), the ligand binding domain of ERα contains 11 alpha helices (H1, H3-H12) folded into a three layered antiparallel alpha helical sandwic…”
BackgroundEstrogen receptor α is a putative substrate for the BRCA1 ubiquitin ligase
Eakin, C. M., MacCoss, M. J., Finney, G. L., & Klevit, R. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610887104 · Cited by 192
Activation of Nuclear Receptors
Li, Y., Lambert, M. H., & Xu, H. E. (2003) · Structure · doi:10.1016/s0969-2126(03)00133-3 · Cited by 191
Transcription Activation by the Ecdysone Receptor (EcR/USP): Identification of Activation Functions
Hu, X., Cherbas, L., & Cherbas, P. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0287 · Cited by 190
Körner, W., Hanf, V., Schuller, W., Kempter, C., Metzger, J. W., & Hagenmaier, H. (1999) · The Science of The Total Environment · doi:10.1016/s0048-9697(99)80015-1 · Cited by 190
Pharmacophore Fingerprinting. 1. Application to QSAR and Focused Library Design
McGregor, M. J., & Muskal, S. M. (1999) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci980159j · Cited by 189
Métivier, R., Penot, G., Flouriot, G., & Pakdel, F. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.11.0727 · Cited by 156
Manas, E. S., Xu, Z. B., Unwalla, R. J., & Somers, W. S. (2004) · Structure · doi:10.1016/j.str.2004.09.015 · Cited by 188
“Eluted protein was concentrated by a Millipore Ultrafree centrifugalto ER / (Brzozowski et al., 1997; Pike et al., 2000; Shiau filtration device and desalted with a BioRad disposable desaltinget al., 1998; Warnmark et al., 2002), in contrast to the column equilibrated with 50 mM ammonium…”
MethodResultSteroid hormone receptors: Evolution, ligands, and molecular basis of biologic function
Whitfield, G. K., Jurutka, P. W., Haussler, C. A., & Haussler, M. R. (1999) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(1999)75:32+<110::aid-jcb14>3.0.co;2-t · Cited by 188
Potent estrogen agonists based on carborane as a hydrophobic skeletal structure
Endo, Y., Iijima, T., Yamakoshi, Y., Fukasawa, H., Miyaura, C., Inada, M., Kubo, A., & Itai, A. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00016-3 · Cited by 187
“Recent studies on the three-dimensional structure of the complex formed by 17L-estradiol and the human ERK ligand-binding domain (hERKLBD) have revealed the structural requirements for the appearance of estrogenic activity [32,33].”
BackgroundMUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor α
Wei, X., Xu, H., & Kufe, D. (2006) · Molecular Cell · doi:10.1016/j.molcel.2005.11.030 · Cited by 186
Bio-Based Aromatic Epoxy Monomers for Thermoset Materials
Ng, F., Couture, G., Philippe, C., Boutevin, B., & Caillol, S. (2017) · Molecules · doi:10.3390/molecules22010149 · Cited by 185
“By analogy with 17β-estradiol, these two hydroxyl groups are essential to establish interactions with the hydrophobic pocket created by the receptor [74,75].”
BackgroundUltrasensitive detection of endocrine disruptors via superfine plasmonic spectral combs
Liu, L., Zhang, X., Zhu, Q., Li, K., Lu, Y., Zhou, X., & Guo, T. (2021) · Light Science & Applications · doi:10.1038/s41377-021-00618-2 · Cited by 185
Structure of a Biologically Active Estrogen Receptor-Coactivator Complex on DNA
Yi, P., Wang, Z., Feng, Q., Pintilie, G. D., Foulds, C. E., Lanz, R. B., Ludtke, S. J., Schmid, M. F., Chiu, W., & O’Malley, B. W. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.01.025 · Cited by 184
“Thus, in order to locate the LBD domain, we took the approach of aligning the known pseudo 2-fold axis (purple arrow in Figure 4A) in the crystal structure (Brzozowski et al., 1997; Shiau et al., 1998) to the 2-fold symmetry axis of ERa in our map (green arrow in Figure 4A).”
InfluentialDAX-1 Functions as an LXXLL-containing Corepressor for Activated Estrogen Receptors
Zhang, H., Thomsen, J. S., Johansson, L., Gustafsson, J.-Å., & Treuter, E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000567200 · Cited by 184
Self-citationJohansson, L., Thomsen, J. S., Damdimopoulos, A. E., Spyrou, G., Gustafsson, J.-Å., & Treuter, E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.1.345 · Cited by 184
Self-citationHormone Replacement Therapy and Lung Cancer Risk
Schabath, M. B., Wu, X., Vassilopoulou-Sellin, R., Vaporciyan, A. A., & Spitz, M. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0911-3 · Cited by 184
“One possible explanation for the reduction in lung cancer risk may be the ability of estrogen receptors to bind various substrates other than estrogen (45, 46), including the carcinogenic polycyclic aromatic hydrocarbons from cigarette smoke.”
BackgroundHistone H2A.Z is essential for estrogen receptor signaling
Gévry, N. Y., Hardy, S., Jacques, P., Laflamme, L., Svotelis, A., Robert, F., & Gaudreau, L. R. (2009) · Genes & Development · doi:10.1101/gad.1787109 · Cited by 187
“Z into chromatin at the TFF1 promoter following treatment with tamoxifen, an antagonist of AF-2, but not AF-1, activity (Brzozowski et al. 1997; Shiau et al. 1998; Celik et al. 2007).”
BackgroundHuman estrogen receptor-α: regulation by synthesis, modification and degradation
Reid, G., Denger, S., Koš, M., & Gannon, F. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-002-8470-2 · Cited by 188
Expression and Degradation of Androgen Receptor: Mechanism and Clinical Implication
Lee, D. K., & Chang, C. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030261 · Cited by 183
Engineering of a Mouse for the in Vivo Profiling of Estrogen Receptor Activity
Ciana, P. (2001) · Molecular Endocrinology · doi:10.1210/me.15.7.1104 · Cited by 182
The role of androgen receptor mutations in prostate cancer progression.
Brooke, G., & Bevan, C. (2009) · Current Genomics · doi:10.2174/138920209787581307 · Cited by 181
Molecular Markers of Endocrine Disruption in Aquatic Organisms
Rotchell, J., & Ostrander, G. (2003) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937400306476 · Cited by 181
“These features include amino acids involved in receptor transactivation (Danielian et al., 1992), dimerization (Tanenbaum et al., 1998), and ligand binding (Brzozowski et al., 1997).”
BackgroundHuang, Q., & Weber, W. J. (2005) · Environmental Science & Technology · doi:10.1021/es050036x · Cited by 181
Estrogen receptor transcription and transactivation Basic aspects of estrogen action
Nilsson, S. V., & Gustafsson, J.-Α. (2000) · Breast Cancer Research · doi:10.1186/bcr81 · Cited by 181
Self-citationNuclear Hormone Receptor Targeted Virtual Screening
Schapira, M., Abagyan, R., & Totrov, M. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0300173 · Cited by 180
Vessières, A., Top, S., Beck, W., Hillard, E., & Jaouen, G. (2006) · Dalton Trans. · doi:10.1039/b509984f · Cited by 180
Structural basis for nuclear hormone receptor DNA binding
Helsen, C., Kerkhofs, S., Clinckemalie, L., Spans, L., Laurent, M. R., Boonen, S., Vanderschueren, D., & Claessens, F. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.07.025 · Cited by 180
Edwards, D. P. (2000) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1009503029176 · Cited by 184
“When bound to antagonist, helix 12 rotates nearly 130 to occupy the hydrophobic groove on the surface of the LBD that forms the coactivator-binding site (48,91).”
BackgroundLi, X., Huang, J. L., Yi, P., Bambara, R. A., Hilf, R., & Muyan, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.17.7681-7694.2004 · Cited by 183
“Upon E2 binding, the LBD undergoes a conformational change by which the helix 12 located at the carboxyl terminus of the LBD is realigned over the ligand-binding pocket ( 3 , 35).”
BackgroundKatzenellenbogen, B. S., & Katzenellenbogen, J. A. (2002) · Science · doi:10.1126/science.1070442 · Cited by 179
Centenera, M. M., Harris, J. M., Tilley, W. D., & Butler, L. M. (2008) · Molecular Endocrinology · doi:10.1210/me.2008-0017 · Cited by 145
Vo, N., Fjeld, C., & Goodman, R. H. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.18.6181-6188.2001 · Cited by 154
“GST pull-down assays verified that only the fragment containing the PXDLS motif, GSTRIP140 (1-495), was capable of interacting with CtBP (Fig.”
BackgroundMethodInfluentialP/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor
McMahon, C., Suthiphongchai, T., DiRenzo, J., & Ewen, M. E. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5382 · Cited by 178
Xenoestrogen-Induced ERK-1 and ERK-2 Activation via Multiple Membrane-Initiated Signaling Pathways
Bulayeva, N. N., & Watson, C. S. (2004) · Environmental Health Perspectives · doi:10.1289/ehp.7175 · Cited by 178
“Xenoestrogens are highly diverse in structure, and the conformation of different xenoestrogen–ER complexes could be significantly different from that of an E2–ER complex (Brzozowski et al. 1997; Suzuki et al. 2001; van Lipzig et al. 2004).”
BackgroundStructure-Based Design of Estrogen Receptor-β Selective Ligands
Manas, E. S., Unwalla, R. J., Xu, Z. B., Malamas, M. S., Miller, C. P., Harris, H. A., Hsiao, C., Akopian, T., Hum, W.-T., Malakian, K., et al. (2004) · Journal of the American Chemical Society · doi:10.1021/ja047633o · Cited by 178
Unbinding of Retinoic Acid from its Receptor Studied by Steered Molecular Dynamics
Kosztin, D., Izrailev, S., & Schulten, K. (1999) · Biophysical Journal · doi:10.1016/s0006-3495(99)77188-2 · Cited by 178
“, 1995), the estrogen receptor (ER) bound to agonist and antagonist (Brzozowski et al., 1997; Tanenbaum et al., 1998), and progesterone complexed to its receptor (PR) (Williams and Sigler, 1998) have been resolved recently and have provided insight into the mechanism of hormone binding.”
BackgroundInfluentialMolecular mechanisms of tamoxifen-associated endometrial cancer (Review)
Hu, R., Hilakivi-Clarke, L. A., & Clarke, R. C. (2015) · Oncology Letters · doi:10.3892/ol.2015.2962 · Cited by 178
“In breast cancer cells, tamoxifen acts as an ER antagonist by competing with estrodiol for binding, and by inducing conformational changes that block the interaction of ER with co-activator proteins (45).”
JORDAN, V (2007) · Steroids · doi:10.1016/j.steroids.2007.07.009 · Cited by 177
“These structure function studies, that created hypothetical models of the ligand-ER/complex, were rapidly advanced with the first reports of the x-ray crystallography of the estrogen, 4hydroxytamoxifen[59] or raloxifene ER[60] complexes.”
BackgroundGlyphosate and the key characteristics of an endocrine disruptor: A review
Muñoz, J. P., Bleak, T. C., & Calaf, G. M. (2021) · Chemosphere · doi:10.1016/j.chemosphere.2020.128619 · Cited by 177
Hestermann, E. V., Stegeman, J. J., & Hahn, M. E. (2000) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2000.9026 · Cited by 177
“Binding of an antagonist to the estrogen receptor displaces an alpha helix relative to its position when an agonist is bound (Brzozowski et al., 1997), preventing binding of a transcriptional coactivator to the receptor (Shiau et al.”
BackgroundLooking at nuclear receptors from a new angle
Helsen, C., & Claessens, F. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.09.009 · Cited by 177
“This repositioned helix 12 forms a platform for coactivator binding (Brzozowski et al., 1997; Parker and White, 1996).”
BackgroundFate and removal of estrogens in municipal wastewater
Racz, L., & Goel, R. K. (2010) · Journal of Environmental Monitoring · doi:10.1039/b917298j · Cited by 179
The Nuclear Receptor Superfamily and Drug Discovery
Moore, J. T., Collins, J. L., & Pearce, K. H. (2006) · ChemMedChem · doi:10.1002/cmdc.200600006 · Cited by 150
Marsaud, V., Gougèlet, A., Maillard, S., & Renoir, J. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0269 · Cited by 179
Billas, I. L., Moulinier, L., Rochel, N., & Moras, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008926200 · Cited by 176
Adoption and Foster Care by Gay and Lesbian Parents in the United States
Gates, G. J., Macomber, J. E., Badgett, M. L., & Prickett, K. (2007) · eScholarship (California Digital Library) · doi:10.25455/wgtn.16920616 · Cited by 176
Estrogen receptors and endocrine diseases: lessons from estrogen receptor knockout mice
Mueller, S. O., & Korach, K. S. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00105-9 · Cited by 176
Xie, W. (1999) · Molecular Endocrinology · doi:10.1210/me.13.12.2151 · Cited by 151
Brinton, R. D. (2001) · Learning & Memory · doi:10.1101/lm.39601 · Cited by 175
“The interaction between ER and coregulators can be negatively regulated by antiestrogens, as in the case of tamoxifen and raloxifene which block the interaction between ER and coactivators (Brzozowski et al. 1997; Shiau et al. 1998).”
BackgroundJohansson, L., Båvner, A., Thomsen, J. S., Färnegårdh, M., Gustafsson, J.-Å., & Treuter, E. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.4.1124-1133.2000 · Cited by 157
“Importantly, as seen in the crystal structures of the LBDs (3, 4, 38), not all three critical NR box core residues (positions 11, 3, and 4) are exposed to the surface, providing a possible explanation for why LXXLL-related motifs within the dimerization helix 10 cannot function as AF-2 binding motifs.”
BackgroundSelf-citationFan, M., Park, A., & Nephew, K. P. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0111 · Cited by 174
Zama, A. M., & Uzumcu, M. (2009) · Endocrinology · doi:10.1210/en.2009-0499 · Cited by 174
Selective estrogen receptor modulation: a personal perspective.
Jordan, V. C. (2001) · PubMed · Cited by 176
Multi-dimensional QSAR in drug discovery
Lill, M. A. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.08.004 · Cited by 174
Wärnmark, A., Treuter, E., Gustafsson, J.-Å., Hubbard, R. E., Brzozowski, A. M., & Pike, A. C. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200764200 · Cited by 173
Self-citationNuclear Receptors: One Big Family
McEwan, I. J. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-575-0_1 · Cited by 173
Emerging Molecular Approaches to Pain Therapy
Williams, M., Kowaluk, E. A., & Arneric, S. P. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9805034 · Cited by 172
Shafei, A., Ramzy, M. M., Hegazy, A. I., Husseny, A. K., EL-hadary, U. G., Taha, M. M., & Mosa, A. A. (2018) · Gene · doi:10.1016/j.gene.2018.01.016 · Cited by 174
Reid, G., Métivier, R., Lin, C., Denger, S., Ibberson, D., Ivacevic, T., Brand, H., Beneš, V., Liu, E. T., & Gannon, F. (2005) · Oncogene · doi:10.1038/sj.onc.1208662 · Cited by 173
“…Nature Publishing Group All rights reserved 0950-9232/05 $30.00 www.nature.com/onc that associate with intermediate transcription factors, which, in turn, activate transcription by recruiting polymerase II to the target promoter (Brzozowski et al., 1997; Metivier et al., 2003; Reid et al., 2003).”
BackgroundInfluentialGobinet, J., Poujol, N., & Sultan, C. (2002) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(02)00364-7 · Cited by 172
The regulation of adipose tissue health by estrogens
Steiner, B. M., & Berry, D. C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.889923 · Cited by 171
“Estrogen can bind and activate two estrogen receptors (ERs), alpha and beta (ERa; ERb) (23).”
Background
Metadata
- Authors
- Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M.
- Affiliations
- University of York (GB)
- Karo Pharma (Sweden) (SE)
- University of Chicago (US)
- Corresponding author
- Hubbard, Roderick E.
- ORCID
- Venue
- Nature
- Published
- 1997-10
- Volume
- 389
- Issue
- 6652
- Pages
- 753-758
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2101738855
- Cited by
- 3,355
- References
- 29
- Citations by year
- 2026: 49 · 2025: 55 · 2024: 55 · 2023: 61 · 2022: 62 · 2021: 91 · 2020: 55 · 2019: 75 · 2018: 73 · 2017: 65 · 2016: 72 · 2015: 74 · 2014: 94 · 2013: 105 · 2012: 104
- FWCI
- 94.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Keywords
- oestrogen receptor, ligand-binding domain, estradiol, raloxifene, selective estrogen receptor modulators, crystal structure, transcriptional regulation
- MeSH terms
- Binding Sites, Estradiol, Estrogen Antagonists, Humans, Models, Molecular, Piperidines, Protein Conformation, Receptors, Estrogen, Crystallography, X-Ray, Raloxifene Hydrochloride
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.